- Home
- RDY vs BMRN Comparison
RDY vs BMRN Comparison
Compare RDY & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDY
- BMRN
- Stock Information
- Founded
- RDY 1984
- BMRN 1996
- Country
- RDY India
- BMRN United States
- Employees
- RDY N/A
- BMRN N/A
- Industry
- RDY Biotechnology: Pharmaceutical Preparations
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- RDY Health Care
- BMRN Health Care
- Exchange
- RDY Nasdaq
- BMRN Nasdaq
- Market Cap
- RDY 11.6B
- BMRN 9.9B
- IPO Year
- RDY N/A
- BMRN 1999
- Fundamental
- Price
- RDY $13.88
- BMRN $54.34
- Analyst Decision
- RDY Strong Buy
- BMRN Buy
- Analyst Count
- RDY 1
- BMRN 19
- Target Price
- RDY $16.90
- BMRN $90.26
- AVG Volume (30 Days)
- RDY 1.1M
- BMRN 2.8M
- Earning Date
- RDY 10-24-2025
- BMRN 10-27-2025
- Dividend Yield
- RDY 0.51%
- BMRN N/A
- EPS Growth
- RDY 9.95
- BMRN 59.53
- EPS
- RDY 0.79
- BMRN 2.68
- Revenue
- RDY $3,851,623,984.00
- BMRN $3,094,001,000.00
- Revenue This Year
- RDY $6.29
- BMRN $13.32
- Revenue Next Year
- RDY $2.61
- BMRN $7.51
- P/E Ratio
- RDY $17.55
- BMRN $20.23
- Revenue Growth
- RDY 14.10
- BMRN 12.39
- 52 Week Low
- RDY $12.26
- BMRN $50.76
- 52 Week High
- RDY $16.17
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- RDY 49.14
- BMRN 53.26
- Support Level
- RDY $13.37
- BMRN $50.76
- Resistance Level
- RDY $13.52
- BMRN $53.49
- Average True Range (ATR)
- RDY 0.24
- BMRN 1.89
- MACD
- RDY 0.02
- BMRN 0.30
- Stochastic Oscillator
- RDY 49.31
- BMRN 57.78
About RDY Dr. Reddy's Laboratories Ltd
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.